FDA warned Cosmetic Specialty Labs after an inspection found manufacturing failures in OTC drugs and an unlisted product.
What happened
FDA inspected the drug manufacturing facility in Lawton, Oklahoma, from September 11 to September 20, 2023. It found current good manufacturing practice (CGMP) failures, including release of a batch without complete finished-product test results and inadequate investigations, stability testing, and annual product reviews. FDA also found inadequate process validation, missing identity testing for high-risk components such as ethanol, glycerin, and propylene glycol, inadequate cleaning validation, and an unlisted drug product.
What FDA found
The quality unit failed to ensure adequate investigations, stability testing, annual product reviews, and complete testing before batch release.
21 CFR 211.22; 21 CFR 211.192; 21 CFR 211.166(a); 21 CFR 211.180(e)Process validation was inadequate and lacked microbiological testing and current active ingredient specifications.
21 CFR 211.100(a)The firm did not test incoming components for identity and relied on supplier certificates; ethanol was not tested for methanol and glycerin/propylene glycol were not tested for diethylene glycol (DEG) or ethylene glycol (EG).
21 CFR 211.84(d)(1) and (2)Cleaning validation and cleaning procedures were inadequate for shared equipment used to make multiple OTC drugs.
21 CFR 211.67(b)A drug product was not listed with FDA.
section 510(j) of the FD&C Act; 21 CFR 207.41
What FDA wants
FDA asks the company to correct the violations promptly and submit detailed remediation plans, including independent assessments and retrospective reviews. It specifically requires diethylene glycol and ethylene glycol test results within 30 calendar days.
Who should pay attention
- brands that buy OTC drugs from this contract manufacturer
- companies using ethanol, glycerin, or propylene glycol in drug products
- retailers and consumers of hand sanitizers, sunscreens, and pain relievers
This is a summary. Read the original letter on fda.gov.